Perceptive Pharma Research | Richmond, TX
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD).
Secondary objectives of the study are to:
The total duration for a participant in the double-blind period only is 66 weeks; and for a participant in the open-label extension (OLE) period, up to an additional 268 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
NOTE- Additional criteria may apply, please contact the investigator for more information
Exclusion criteria
NOTE- Additional criteria apply, please contact the investigator for more information
Primary purpose
Allocation
Interventional model
Masking
218 participants in 4 patient groups
Loading...
Central trial contact
Teva U.S. Medical Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal